Expansion of the Medical Devices Business through the Acquisition of Aimedic MMT
First written in FY2019. 14 of 20 entries say "Advanced", first in FY2020-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026WorsenedAnnual report
「Other businesses include the robot-related devices, electronic materials and medical equipment businesses, among others. Revenue was ¥6,954 million, up 14.1% year on year, while segment profit was ¥242 million, down 18.1%.」
The Other Businesses segment, including the medical device and healthcare equipment businesses, posted higher revenue, while segment profit declined 18.1% year on year. - 2026-05-14AdvancedFinancial Results Presentation
「Continued launches in the medical equipment and healthcare equipment markets Further expand sales of the absorbable bone-regeneration material e=Bone®」
Identifies continued market launches and expanded sales of e=Bone® as specific initiatives for the new medical equipment and healthcare equipment businesses. - FY2025AdvancedAnnual report
「The Other Businesses segment comprises the robot-related devices business, electronic materials business and medical device business, among others. Revenue was ¥6,095 million, up 13.9% year on year, and segment profit was ¥296 million, up 306.2% year on year.」
The Other Businesses segment, including the medical device business and other operations, posted year-on-year increases in revenue and segment profit. - FY2025-H1AdvancedAnnual report
「The Other businesses comprise the robot-related devices, Electronic Materials and medical device businesses, among others. Revenue was ¥2,917 million, up 10.8% year on year, and segment profit was ¥164 million, compared with a segment loss of ¥47 million in the same period of the previous year.」
The Other Businesses segment, which includes the medical device business operated through Aimedic MMT, posted higher revenue and turned a segment loss in the same period of the previous year into a profit. - FY2024AdvancedAnnual report
「In our new businesses, we will work to establish the electronic materials business and the medical device and healthcare equipment business as new core businesses.」
The electronic materials business and medical device and healthcare equipment business were positioned as the pillars of the new businesses, with a policy of continuing to expand sales and commercialize products including e=Bone®, PULL-OUT ALERT®, ResMo® and B4S™. - FY2024-Q3AdvancedAnnual report
「We began selling PULL-OUT ALERT®, a healthcare device using our independently developed C-STRETCH® elastic strain sensor that detects removal movements. The Other Businesses segment comprises the robot-related devices business, electronic materials business and medical device business, among others. Revenue was ¥3,989 million, up 7.2% year on year, and segment profit was ¥53 million, up 59.0% year on year.」
In addition to the launch of sales of a healthcare device using C-STRETCH®, the disclosure reports increases in revenue and segment profit in the Other Businesses segment, which includes the medical device business and other operations. - FY2024-Q2WorsenedAnnual report
「The Other Businesses segment comprises the robot-related devices business, electronic materials business and medical device business, among others. Revenue was ¥2,634 million, up 7.6% year on year, while the segment loss was ¥47 million, compared with a segment loss of ¥12 million in the same period of the previous year.」
The Other Businesses segment, including the medical device business, posted higher revenue, while its segment loss widened from ¥12 million in the same period of the previous year to ¥47 million. - FY2023AdvancedAnnual report
「In the medical device and healthcare equipment businesses, we will seek to expand sales of products using C-STRETCH®, an elastic strain sensor, including ResMo® (ResMo), the first medical device in the respiratory field, and B4S™ (B4S), a swallowing-motion monitor. We will also commercialize e=Bone® (e=Bone), an absorbable bone-regeneration material developed from the results of industry-academia collaboration and based on our group's core technologies.」
In addition to expanding sales of ResMo® and B4S™ through Aimedic MMT, the commercialization of e=Bone® through industry-academia collaboration was identified as a new medical and healthcare business initiative. - FY2023-Q3RestatedAnnual report
「The Other Businesses segment comprises the robot-related devices business, electronic materials business and medical device business, among others. Revenue was ¥3,720 million, down 5.0% year on year, while segment profit was ¥33 million, down 88.0% year on year, partly due to the impact of lower reimbursement prices for core products in the medical device business.」
The impact of lower reimbursement prices for core products in the medical device business continued, resulting in lower revenue in the Other Businesses segment and an 88.0% year-on-year decline in segment profit. The segment returned to profit from a loss in the previous quarter. - FY2023-Q2WorsenedAnnual report
「The Other businesses comprise the robot-related devices, Electronic Materials and medical device businesses, among others. Revenue was ¥2,449 million, down 5.1% year on year, while the segment recorded a loss of ¥12 million, compared with segment profit of ¥147 million in the same period of the previous year, partly due to the impact of lower reimbursement prices for core products in the medical device business.」
In the medical device business expanded through Aimedic MMT, the Other Businesses segment posted lower revenue and a segment loss, partly due to the impact of lower reimbursement prices for its core products. - FY2022AdvancedAnnual report
「Aimedic MMT, a consolidated subsidiary, developed and began selling ResMo®, a medical device applying the technology of C-STRETCH® (C-STRETCH), an elastic strain sensor developed independently by our company. It also began selling B4S™ (B4S), a swallowing-motion monitor and healthcare device using C-STRETCH®.」
In the medical device business operated through Aimedic MMT, sales of the C-STRETCH® application products ResMo® and B4S™ began. - FY2022-Q3AdvancedAnnual report
「Amid expectations of growing social needs in the field of swallowing, the company began selling the B4S™ swallowing-motion monitor (B4S), a healthcare device using its proprietary C-STRETCH® stretchable strain sensor, as a new product.」
In the medical device and healthcare business following the acquisition of Aimedic MMT, sales of B4S™, a product applying C-STRETCH®, began. - FY2022-Q1AdvancedAnnual report
「In the medical device field, one of the new business pillars the Company has pursued, its consolidated subsidiary Aimedic MMT developed and began selling ResMo, a medical device that applies the technology of C-STRETCH®, an extensible strain sensor independently developed by the Company, through distributors.」
Aimedic MMT developed the medical device ResMo applying C-STRETCH® and began sales through distributors. Following the acquisition, commercialization of new products progressed in the medical device business. - FY2021AdvancedAnnual report
「We also obtained ISO 13485:2016 quality management system certification at our head office facility to maintain the safety and quality of medical devices.」
ISO 13485:2016 certification was obtained at our head office facility as the foundation for quality management in the medical device business. - FY2021-Q3AdvancedAnnual report
「In the medical equipment field, which we have pursued as one of our new business pillars, our consolidated subsidiary Aimedic MMT Co., Ltd. developed and began selling “AT Measure,” applying the technology of “C-STRETCH®,” an elastic strain sensor developed independently by our Company.」
Aimedic MMT developed an AT Measure applying C-STRETCH® technology and began sales. Following the acquisition, the medical device business made progress in developing and commercializing specific products. - FY2020WorsenedAnnual report
「The consolidated statement of profit or loss for our group for the current consolidated fiscal year includes revenue and loss for the year generated by Aimedic MMT after the business combination date of ¥2,605 million and ¥2,944 million, respectively. The loss for the year of ¥2,944 million comprises Aimedic MMT's standalone profit for the year of ¥329 million and a goodwill impairment loss of ¥3,274 million.」
Following the acquisition of Aimedic MMT, revenue of ¥2,605 million was recorded, while a loss for the year of ¥2,944 million, including a goodwill impairment loss of ¥3,274 million, was recorded. - FY2020-Q3AdvancedAnnual report
「The condensed interim consolidated statement of profit or loss for our group's cumulative third-quarter period includes revenue and quarterly profit generated by Aimedic MMT after the business combination date of ¥1,875 million and ¥238 million, respectively.」
For the cumulative third-quarter results after the acquisition of Aimedic MMT, revenue of ¥1,875 million and quarterly profit of ¥238 million were included in consolidated results. The purchase price allocation for the business combination was also finalized in the third quarter, resulting in goodwill of ¥11,802 million. - FY2020-Q2AdvancedAnnual report
「The condensed interim consolidated statement of profit or loss for our group's cumulative second-quarter period includes revenue and quarterly profit generated by Aimedic MMT after the business combination date of ¥1,128 million and ¥168 million, respectively.」
Following the acquisition of Aimedic MMT, revenue of ¥1,128 million and quarterly profit of ¥168 million generated after the business combination date were included in consolidated results. - FY2020-Q1AdvancedAnnual report
「As of 8 May 2019, we acquired all shares of Aimedic MMT Co., Ltd. and made it a subsidiary. The revenue and quarterly profit generated by Aimedic MMT after the business combination date were ¥419 million and ¥37 million, respectively.」
Following the acquisition and consolidation of Aimedic MMT as a subsidiary, revenue of ¥419 million and quarterly profit of ¥37 million generated after the business combination date were included in consolidated results. - FY2019First statedAnnual report
「As of 8 May 2019, we acquired all shares of Aimedic MMT Co., Ltd. Going forward, we will grow our group's medical device business by leveraging the company's strong brand and sales capabilities.」
On 8 May 2019, all shares were acquired, and a strategy was disclosed to grow the medical device business by leveraging Aimedic MMT's brand and sales capabilities. The acquisition consideration was ¥10,450 million.